CD34 and chronic graft versus host disease: While six patients (7% total cohort) suffered from chronic GVHD beyond five years post-transplant, only two had moderate/severe requiring systemic treatment and defined as events, one SCID patient after a CD34 + top-up and the other following RIC MRD allograft for XLP (P15 and P20).